Last Price$137.11.5%
Market Cap$237.5B
LTM Total Equity
$47.9B
YoY Growth
+23.4%
3Y CAGR
+10.0%
5Y CAGR
+8.9%
Stock quality & Intrinsic value
7/10
29.8% undervalued
Abbott Laboratories Total Equity
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Equity | $14.4B | $14.1B | $17.8B | $17.5B | $22.9B | $22.5B | $24.5B | $26.8B | $25.3B | $21.6B | $21.3B | $20.7B | $31.1B | $30.7B | $31.3B | $33.0B | $36.0B | $36.9B | $38.8B | $47.9B |
Overvalued or undervalued?
Check the intrinsic value for ABT
and see if it's the right time to invest.
Abbott Laboratories (ABT) Total Equity comparison analysis
General
LTM Total Equity
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Abbott LaboratoriesABT
$47.9B
23.4%
10.0%
8.9%
Median Peer Set
$11.3B
9.4%
3.3%
16.3%
Medtronic plcMDT
$49.6B
(4.6%)
(2.0%)
(0.9%)
Stryker CorporationSYK
$43.0B
131.1%
42.4%
27.4%
Boston Scientific CorporationBSX
$22.0B
12.7%
9.8%
9.7%
Zimmer Biomet Holdings, Inc.ZBH
$14.4B
15.6%
4.5%
3.1%
Koninklijke Philips N.V.PHG
$12.5B
(6.3%)
(5.9%)
(0.9%)
Edwards Lifesciences CorporationEW
$10.1B
49.8%
19.9%
19.4%
STERIS plcSTE
$6,428.5M
0.0%
(1.0%)
13.6%
Align Technology, Inc.ALGN
$3,852.0M
6.1%
2.1%
23.4%
DexCom, Inc.DXCM
$2,102.6M
1.6%
(2.3%)
19.0%
Insulet CorporationPODD
$1,211.6M
65.4%
29.6%
74.0%
ABT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 22,337.8 13.5% | 22,476.3 0.6% | 25,914.2 15.3% | 29,527.6 13.9% | 30,765.0 4.2% | 35,167.0 14.3% | 38,851.0 10.5% | 39,874.0 2.6% | 21,848.0 (45.2%) | 20,247.0 (7.3%) | 20,405.0 0.8% | 20,853.0 2.2% | 27,390.0 31.3% | 30,578.0 11.6% | 31,904.0 4.3% | 34,608.0 8.5% | 43,075.0 24.5% | 43,653.0 1.3% | 40,109.0 (8.1%) | 41,950.0 4.6% |
| Cost of Goods Sold (COGS) | 10,641.1 | 9,815.1 | 11,422.0 | 12,612.0 | 13,209.0 | 14,665.0 | 15,541.0 | 15,120.0 | 10,040.0 | 9,218.0 | 8,747.0 | 9,024.0 | 12,337.0 | 12,706.0 | 13,231.0 | 15,003.0 | 18,537.0 | 19,142.0 | 17,975.0 | 18,706.0 |
% margin | 11,696.7 52.4% | 12,661.2 56.3% | 14,492.2 55.9% | 16,915.5 57.3% | 17,556.0 57.1% | 20,502.0 58.3% | 23,310.0 60.0% | 24,754.0 62.1% | 11,808.0 54.0% | 11,029.0 54.5% | 11,658.0 57.1% | 11,829.0 56.7% | 15,053.0 55.0% | 17,872.0 58.4% | 18,673.0 58.5% | 19,605.0 56.6% | 24,538.0 57.0% | 24,511.0 56.1% | 22,134.0 55.2% | 23,244.0 55.4% |
| Operating Expenses | 7,317.3 | 8,605.0 | 9,913.6 | 11,124.4 | 11,150.0 | 14,101.0 | 17,558.0 | 16,381.0 | 9,179.0 | 8,430.0 | 8,791.0 | 8,644.0 | 13,327.0 | 14,222.0 | 14,141.0 | 14,248.0 | 16,113.0 | 16,149.0 | 15,656.0 | 16,419.0 |
| Research & Development Expenses (R&D) | 1,821.2 | 2,255.3 | 2,505.6 | 2,688.8 | 2,744.0 | 3,725.0 | 4,802.0 | 4,322.0 | 1,452.0 | 1,345.0 | 1,405.0 | 1,422.0 | 2,235.0 | 2,300.0 | 2,440.0 | 2,420.0 | 2,742.0 | 2,888.0 | 2,741.0 | 2,844.0 |
| Selling, General & Administrative Expenses (SG&A) | 5,496.1 | 6,349.7 | 7,408.0 | 8,435.6 | 8,406.0 | 10,376.0 | 12,756.0 | 12,059.0 | 6,936.0 | 6,530.0 | 6,785.0 | 6,672.0 | 9,117.0 | 9,744.0 | 9,765.0 | 9,696.0 | 11,324.0 | 11,248.0 | 10,949.0 | 11,697.0 |
% margin | 4,362.3 19.5% | 2,042.2 9.1% | 4,578.5 17.7% | 5,693.8 19.3% | 6,236.0 20.3% | 6,088.0 17.3% | 5,752.0 14.8% | 8,085.0 20.3% | 2,629.0 12.0% | 2,599.0 12.8% | 2,867.0 14.1% | 3,185.0 15.3% | 1,726.0 6.3% | 3,650.0 11.9% | 4,532.0 14.2% | 5,357.0 15.5% | 8,425.0 19.6% | 8,362.0 19.2% | 6,478.0 16.2% | 6,825.0 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 201.2 | 137.8 | 105.5 | 85.2 | 79.2 | 67.0 | 77.0 | 105.0 | 99.0 | 124.0 | 105.0 | 94.0 | 46.0 | 43.0 | 183.0 | 385.0 | 344.0 |
| Interest Expense | 153.7 | 292.3 | 593.1 | 528.5 | 382.0 | 553.1 | 530.1 | 513.0 | 90.0 | 73.0 | 58.0 | 332.0 | 780.0 | 721.0 | 576.0 | 500.0 | 490.0 | 375.0 | 637.0 | 559.0 |
| Pre-tax Income | 4,619.9 | 2,276.4 | 4,469.6 | 5,856.3 | 7,194.0 | 5,713.0 | 5,199.0 | 6,263.0 | 2,521.0 | 2,518.0 | 3,183.0 | 1,413.0 | 2,231.0 | 2,873.0 | 4,077.0 | 4,968.0 | 8,211.0 | 8,306.0 | 6,664.0 | 7,013.0 |
% effective tax rate | 1,247.9 27.0% | 559.6 24.6% | 863.3 19.3% | 1,122.1 19.2% | 1,448.0 20.1% | 1,087.0 19.0% | 470.0 9.0% | 300.0 4.8% | 138.0 5.5% | 797.0 31.7% | 577.0 18.1% | 350.0 24.8% | 1,878.0 84.2% | 539.0 18.8% | 390.0 9.6% | 497.0 10.0% | 1,140.0 13.9% | 1,373.0 16.5% | 941.0 14.1% | (6,389.0) (91.1%) |
% margin | 3,372.1 15.1% | 1,716.8 7.6% | 3,606.3 13.9% | 4,880.7 16.5% | 5,745.8 18.7% | 4,626.2 13.2% | 4,728.0 12.2% | 5,963.0 15.0% | 2,576.0 11.8% | 2,284.0 11.3% | 4,423.0 21.7% | 1,400.0 6.7% | 477.0 1.7% | 2,368.0 7.7% | 3,687.0 11.6% | 4,495.0 13.0% | 7,071.0 16.4% | 6,933.0 15.9% | 5,723.0 14.3% | 13,402.0 31.9% |
| EPS | 2.17 | 1.12 | 2.34 | 3.16 | 3.72 | 2.99 | 3.01 | 3.78 | 1.66 | 1.51 | 3.00 | 0.95 | 0.27 | 1.35 | 2.07 | 2.52 | 3.97 | 3.94 | 3.30 | 7.74 |
| Diluted EPS | 2.16 | 1.12 | 2.31 | 3.13 | 3.70 | 2.97 | 3.01 | 3.75 | 1.64 | 1.50 | 2.94 | 0.94 | 0.27 | 1.34 | 2.06 | 2.50 | 3.94 | 3.91 | 3.27 | 7.67 |
% margin | 6,220.2 27.8% | 4,251.3 18.9% | 6,433.4 24.8% | 8,223.6 27.9% | 9,493.9 30.9% | 9,138.3 26.0% | 9,260.7 23.8% | 3,496.0 8.8% | 3,452.0 15.8% | 4,216.0 20.8% | 4,833.0 23.7% | 3,070.0 14.7% | 6,132.0 22.4% | 7,116.0 23.3% | 7,771.0 24.4% | 8,789.0 25.4% | 12,742.0 29.6% | 12,380.0 28.4% | 10,605.0 26.4% | 10,834.0 25.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Abbott Laboratories's Total Equity?
As of today, Abbott Laboratories's last 12-month Total Equity is $47.9B, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Abbott Laboratories's Total Equity growth rate?
Over the last year, Abbott Laboratories's Total Equity growth was 23.4%. The average annual Total Equity growth rates for Abbott Laboratories have been 12.1% over the past three years, 8.9% over the past five years.
3) Is Abbott Laboratories's Total Equity growth rate Good?
Over the last year, Abbott Laboratories's Total Equity growth was 23.4%, which is higher than industry growth of (0.2%). It indicates that Abbott Laboratories's Total Equity growth is Good.